Market Research Logo

Neutropenia - Pipeline Review, H2 2015

Neutropenia - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Neutropenia - Pipeline Review, H2 2015’, provides an overview of the Neutropenia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Neutropenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neutropenia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Neutropenia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Neutropenia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Neutropenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Neutropenia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Neutropenia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Neutropenia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Neutropenia Overview
Therapeutics Development
Pipeline Products for Neutropenia - Overview
Neutropenia - Therapeutics under Development by Companies
Neutropenia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Neutropenia - Products under Development by Companies
Neutropenia - Companies Involved in Therapeutics Development
Apotex, Inc.
Biocon Limited
Biogenomics Limited
Cellerant Therapeutics, Inc.
Coherus BioSciences, Inc.
CSL Limited
Dr. Reddy's Laboratories Limited
Inbiopro Solutions Pvt. Ltd.
Ligand Pharmaceuticals, Inc.
NAL Pharmaceuticals Ltd.
Prolong Pharmaceuticals
Richter Gedeon Nyrt.
Sandoz International GmbH
Therapeutic Proteins International, LLC
Toko Pharmaceutical Industries Co., Ltd.
USV Limited
Neutropenia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ACN-8337 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CSL-324 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EC-18 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
filgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
filgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
filgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
filgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
granulocyte colony-stimulating factor biobetter - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IBPB-004IG - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LG-7455 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pegfilgrastim (recombinant) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
romyelocel-L - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ST-7 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tamibarotene - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Neutropenia - Recent Pipeline Updates
Neutropenia - Dormant Projects
Neutropenia - Product Development Milestones
Featured News & Press Releases
Nov 18, 2015: Regulatory submission for Sandoz' proposed biosimilar pegfilgrastim accepted by the FDA
Oct 01, 2015: Coherus Announces Topline Results of CHS-1701 Pharmacokinetic and Pharmacodynamic Biosimilarity Study
Mar 17, 2015: Coherus Finalizes CHS-1701 BLA Enabling Clinical Program and Initiates Pivotal Pharmacokinetic and Pharmacodynamic Study
Dec 17, 2014: Apotex Announces FDA Has Accepted For Filing its Biosimilar Application for Pegfilgrastim
Dec 09, 2013: Ligand Announces Positive Preclinical Data on Small-Molecule G-CSF Receptor Agonist at the 55th Annual Meeting of the American Society of Hematology
May 30, 2012: Aequus Presents Proof Of Concept Data Of GlycoPolymer Technology At International Symposium For Polymer Therapeutics
Dec 12, 2011: Ligand Announces Positive Preclinical Data On Small-Molecule GCSF Receptor Agonist At ASH Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Neutropenia, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Neutropenia - Pipeline by Apotex, Inc., H2 2015
Neutropenia - Pipeline by Biocon Limited, H2 2015
Neutropenia - Pipeline by Biogenomics Limited, H2 2015
Neutropenia - Pipeline by Cellerant Therapeutics, Inc., H2 2015
Neutropenia - Pipeline by Coherus BioSciences, Inc., H2 2015
Neutropenia - Pipeline by CSL Limited, H2 2015
Neutropenia - Pipeline by Dr. Reddy's Laboratories Limited, H2 2015
Neutropenia - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2015
Neutropenia - Pipeline by Ligand Pharmaceuticals, Inc., H2 2015
Neutropenia - Pipeline by NAL Pharmaceuticals Ltd., H2 2015
Neutropenia - Pipeline by Prolong Pharmaceuticals, H2 2015
Neutropenia - Pipeline by Richter Gedeon Nyrt., H2 2015
Neutropenia - Pipeline by Sandoz International GmbH, H2 2015
Neutropenia - Pipeline by Therapeutic Proteins International, LLC, H2 2015
Neutropenia - Pipeline by Toko Pharmaceutical Industries Co., Ltd., H2 2015
Neutropenia - Pipeline by USV Limited, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Neutropenia Therapeutics - Recent Pipeline Updates, H2 2015
Neutropenia - Dormant Projects, H2 2015
List of Figures
Number of Products under Development for Neutropenia, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Targets, H2 2015
Number of Products by Stage and Targets, H2 2015
Number of Products by Mechanism of Actions, H2 2015
Number of Products by Stage and Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report